The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2022 | The prognostic impact of pre-transplant MRD-positivity in patients with AML
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses whether a measurable residual disease (MRD) negative status should be achieved prior to stem cell transplantation (SCT) in patients with acute myeloid leukemia (AML). There is a strong correlation between pre-transplant MRD status and relapse rate, with the field of acute lymphoblastic leukemia (ALL) setting a precedent of administering blinatumomab in MRD-positive patients prior to transplant. Whilst this strategy cannot be directly translated to patients with AML, maintenance therapy consisting of sorafenib is currently used in a number of patients. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
